📊 EARNINGS SEASON ANALYZER — MARCH 27, 2026

Earnings Report Card: How 4 Major Companies Compare to Titan Biotech’s Quality Benchmarks

By Manish Goel | multibaggershares.com

This week, several Indian companies announced their quarterly results. As a value investor, I always ask one simple question: “Does this company match the quality benchmark set by Titan Biotech?” Today, we compare BSE Ltd, Biocon, Bank of India, and Indian Bank against our gold-standard benchmark — and the results are revealing.

🏆 The Gold Standard: Titan Biotech (Q3 FY26)

This is what a quality small-cap multibagger looks like. Let’s see how others compare…

1. BSE Ltd — Grade: A-

The Good: BSE Ltd delivered record-breaking Q3 FY26 results with revenue surging 62% YoY to ₹1,244 crore and net profit soaring 173% to ₹596.59 crore. Operating EBITDA tripled to ₹732 crore with a spectacular 59% margin. The exchange processed 21.7 crore mutual fund transactions — a 21% increase — commanding 87.4% market share in mutual fund processing.

The Reality Check: While BSE Ltd has a higher profit growth rate of 173% compared to Titan Biotech’s 94%, Titan Biotech delivers the complete package of growth + quality + small market cap. BSE Ltd already has a market cap of ₹30,000+ crore — the massive multibagger returns are already done. Titan Biotech’s small size means far more upside potential for patient investors. BSE is also heavily dependent on market cycles — when markets crash, BSE’s revenue drops dramatically. Titan Biotech sells essential biochemical products with consistent demand.

2. Biocon — Grade: B

The Good: Biocon reported Q3 FY26 revenue of ₹4,173 crore (up 9% YoY) with a dramatic 475% surge in net profit to ₹144 crore. The biosimilars segment grew 9% with EBITDA improving 44% YoY, and the generics business delivered strong 24% YoY growth.

The Reality Check: While Biocon’s 475% profit growth looks impressive on paper, the base was extremely low (coming from near-losses). The ROCE is a dismal 4.36% compared to Titan Biotech’s 16.9%. Biocon carries significant debt from its $5.5 billion Biocon Biologics integration. A 4.36% ROCE means the company is barely generating returns above its cost of capital. Titan Biotech is almost debt-free and generates nearly 4x the return on capital — that’s the difference between real quality and headline-grabbing numbers.

3. Bank of India — Grade: B-

The Good: Bank of India reported interest income of ₹19,052 crore (up 4% YoY) with net profit of ₹2,814 crore (up 6.7% YoY). The bank’s gross NPA improved, indicating strengthening asset quality.

The Reality Check: A 6.7% profit growth from a public sector bank is average at best. Banks are inherently leveraged businesses — they borrow to lend. You cannot compare their balance sheet quality to a debt-free manufacturing company like Titan Biotech. While Bank of India manages ₹7.9 lakh crore in deposits, Titan Biotech’s 94% profit growth with near-zero debt demonstrates far superior capital efficiency and wealth-creation potential for retail investors. PSU banks also face constant government interference and have historically destroyed shareholder value through repeated dilutions.

4. Indian Bank — Grade: B

The Good: Indian Bank delivered net profit of ₹3,061 crore (up 7% YoY) with operating profit crossing the ₹5,000 crore milestone. Net interest income grew 7.5% to ₹6,896 crore, and asset quality improved with gross NPA declining to 2.23%. Deposits grew an impressive 12.6% YoY.

The Reality Check: Indian Bank is performing well for a PSU bank — but 7% profit growth is what you get from a fixed deposit, not from a quality stock. Titan Biotech’s 94% profit growth is literally 13x faster. Indian Bank’s business model depends entirely on interest rate cycles controlled by RBI. Titan Biotech manufactures biochemicals with growing global demand — its growth is driven by business fundamentals, not monetary policy. For long-term wealth creation, the difference is night and day.

🎯 Key Takeaway

This week’s earnings confirm what we’ve been teaching: quality companies like Titan Biotech consistently outperform on the metrics that matter most — profit growth, ROCE, and balance sheet strength.

BSE Ltd had strong results, but it’s already a ₹30,000 Cr company. Biocon’s profit growth looks impressive but it’s built on a weak ROCE and heavy debt. The PSU banks grew profits in single digits. Meanwhile, Titan Biotech delivered 94% profit growth with 16.9% ROCE, near-zero debt, and a 331% stock price return in just one year.

The lesson? Don’t chase headlines. Chase quality. That’s value investing.

⚠️ Important Warning: Say NO to F&O Gambling

SEBI data consistently shows that over 90% of retail traders lose money in Futures & Options. Don’t destroy your wealth chasing quick gains in derivatives. Instead, invest in quality companies for the long term — that’s how real wealth is built.

The companies profiled above have taken decades to build their businesses. Respect the process. Be a patient investor, not a gambler.

📚 Learn Value Investing — Free Course by Manish Goel

Master the art of finding quality stocks like Titan Biotech. Watch the complete “Value Investing with Manish Goel” course playlist on YouTube.

▶ Watch Free Course Playlist

About Manish Goel: Value investor and founder of multibaggershares.com, on a mission to educate 200 million Indian stock market investors about quality investing. Manish identified Titan Biotech at ~₹130, which has since delivered 200%+ returns — a testament to the power of fundamental analysis and patience. His stock picks have been read by India’s top investors including Mohnish Pabrai’s team.

Disclaimer: This article is for educational purposes only and does not constitute financial advice, stock recommendations, or investment guidance. The author may hold positions in the securities mentioned. All data presented is sourced from publicly available quarterly results and is believed to be accurate as of the date of publication. Past performance is not indicative of future results. Always do your own research (DYOR) and consult a SEBI-registered investment advisor before making any investment decisions. Investing in the stock market involves risk, including the risk of loss of principal.